Relmada Therapeutics Stock Investor Sentiment

RLMD Stock  USD 0.43  0.04  7.55%   
About 57% of all Relmada Therapeutics' shareholders are looking to take a long position. The analysis of overall sentiment of trading Relmada Therapeutics stock suggests that some investors are interested at this time. The current market sentiment, together with Relmada Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Relmada Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Relmada Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Relmada Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at accesswire.com         
SHAREHOLDER ACTION ALERT The Schall Law Firm Announces it is Investigating Claims Against Relmada Th...
news
over six months ago at accesswire.com         
INVESTOR ACTION ALERT The Schall Law Firm Announces it is Investigating Claims Against Relmada Thera...
news
over six months ago at news.google.com         
Q2 2024 Earnings Forecast for Relmada Therapeutics, Inc. Issued By Leerink Partnrs - MarketBeat
Google News at Macroaxis
over six months ago at insidermonkey.com         
Relmada Therapeutics, Inc. Q1 2024 Earnings Call Transcript
insidermonkey News
over six months ago at news.google.com         
Earnings call Relmada Therapeutics reports Q1 2024 financials By Investing.com - Investing.com
Google News at Macroaxis
over six months ago at investorplace.com         
RLMD Stock Earnings Relmada Therapeutics Beats EPS for Q1 2024
sbwire news
over six months ago at seekingalpha.com         
Relmada Therapeutics GAAP EPS of -0.72 beats by 0.15
seekingalpha News
over six months ago at gurufocus.com         
Relmada Therapeutics Inc Earnings Call Transcript Highlights Strategic ...
Gurufocus Stories at Macroaxis
over six months ago at finance.yahoo.com         
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Yahoo News
over six months ago at www.macroaxis.com         
Acquisition by Traversa Sergio of 27460 shares of Relmada Therapeutics at 3.9968 subject to Rule 16b...
Macroaxis News
over six months ago at finance.yahoo.com         
Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Web...
Yahoo News
over six months ago at news.google.com         
Relmada Stock Falls After Equity Raise Of 150M To Fund Depression Candidate - AOL
Google News at Macroaxis
over six months ago at news.google.com         
Relmada Therapeutics Stock Price Down 3.3 percent - MarketBeat
Google News at Macroaxis
over six months ago at simplywall.st         
Bullish Relmada Therapeutics Insiders Loaded Up On US695.2k Of Stock
Simply Wall St News at Macroaxis
over six months ago at news.google.com         
RLMD NEWS The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violatio...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Relmada Therapeutics that are available to investors today. That information is available publicly through Relmada media outlets and privately through word of mouth or via Relmada internal channels. However, regardless of the origin, that massive amount of Relmada data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Relmada Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Relmada Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Relmada Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Relmada Therapeutics alpha.

Relmada Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Relmada Therapeutics Stock Price Down 0.3 percent Heres What Happened
10/10/2024
2
Disposition of tradable shares by Ogorman Cedric of Relmada Therapeutics subject to Rule 16b-3
10/16/2024
3
Disposition of 13000 shares by Casamento Charles J of Relmada Therapeutics subject to Rule 16b-3
10/22/2024
4
Acquisition by Schmidt Eric Thomas of 57042 shares of Relmada Therapeutics subject to Rule 16b-3
10/28/2024
5
Relmada Therapeutics GAAP EPS of -0.72 misses by 0.08
11/07/2024
6
Relmada Therapeutics Inc Q3 2024 Earnings Call Highlights Navigating Financial ...
11/08/2024
7
Acquisition by Ence Chuck of 14500 shares of Relmada Therapeutics at 3.8657 subject to Rule 16b-3
11/20/2024
8
Relmada Therapeutics Stock Plummets Losing 80 percent Value - Heres Why
12/04/2024
9
Relmada Therapeutics Rating Lowered to Hold at Mizuho
12/06/2024
10
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
12/09/2024

Complementary Tools for Relmada Stock analysis

When running Relmada Therapeutics' price analysis, check to measure Relmada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relmada Therapeutics is operating at the current time. Most of Relmada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relmada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relmada Therapeutics' price. Additionally, you may evaluate how the addition of Relmada Therapeutics to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios